Sanofi pays Regeneron $1B to expand antibody partnership
The companies aim to develop long-acting antibody drugs as Dupixent's patent approaches.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
Sanofi and Regeneron expanded their partnership. 123 The agreement includes a $1 billion upfront payment. 12 The companies plan to develop long-acting antibody drugs. 1
Why it matters
Dupixent faces an approaching patent cliff. 23
What to watch
The expanded collaboration aims to find successors to Dupixent. 13
Sources · 3
[1]Sanofi builds on immunology alliance with Regeneron for $1B upfront
Endpoints News
[2]Sanofi, Regeneron broaden alliance to find their next Dupixent
BioPharma Dive
[3]STAT+: Sanofi, Regeneron expand partnership after Dupixent success
STAT
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.